Investigation of Cannabinoid 2-receptor Expression in the Brain and Spine of ALS-patients Compared to Healthy Controls With PET (18F-RoSMALS)

Amyotrophic Lateral Sclerosis Clinical Trial

— 18F-RoSMALS  

Official title:

A Monocentric, Controlled, Open Label, Phase I, First-in-human Trial to Investigate the Regional Distribution of [18F]RoSMA-18-d6 in the Brain and Spinal Cord to Assess Cannabinoid Type 2 Receptor (CB2R) Expression in Healthy Volunteers and Patients With Amyotrophic Lateral Sclerosis (ALS) by Positron Emission Tomography (PET)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05880563
• Other study ID #: 18F-RoSMALS
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: August 2023
• Est. completion date: September 2026

Study information

• Verified date: May 2023
• Source: Cantonal Hospital of St. Gallen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical trial is a phase 1 study in which investigations with the weakly radioactive substance [18F]-RoSMA-18-d6 are being carried out for the first time. This radiolabeled substance will be used to study a specific protein in the brain and spinal cord of patients with ALS and healthy individuals. This particular protein, the cannabinoid type 2 receptor, is thought to play a role in the disease process of ALS. Furthermore, it is assumed that this protein is found more frequently in the brain and spinal cord of patients with ALS compared to healthy individuals. The following questions will be answered by this clinical trial. 1. Is this protein found, as suspected, increased in the brain and spinal cord of ALS patients compared to healthy individuals ? 2. Does the amount of this protein change during the course of the disease? 3. Are there any correlations between the observed changes in the amount of protein and the assessment of the course of the disease?

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: September 2026
• Est. primary completion date: September 2026
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria _ALS-patients:

• Age =18 years
• Able to provide written informed consent prior to study participation
• Body weight of = 50 kg and a body mass index (BMI) between 19-30 kg/m2
• Vital signs measured after three minutes resting in the supine position must be within

the following ranges:

• oral body temperature: 35.0-37.5 °C
• systolic blood pressure: 90-140 mm Hg
• diastolic blood pressure: 50-90 mm Hg
• pulse rate: 40-90 bpm
• Clinically probable, probable laboratory supported, or definite ALS-diagnosis according to the revised version of the El Escorial World Federation of Neurology criteria (EEC) (46)
• Disease duration = 18 months since date of diagnosis
• Slow vital capacity (sVC) = 80 % of normal (best of three measurements)
• Pre-study ALSFRS-R progression between disease onset and screening of -0.4 points/month or worse (calculated by ALSFRS-R score decline from 48 divided by months since symptom onset until screening)
• Patient has to be on a stable dose of disease modifying treatments (Edaravone 60 mg i.v. on ten days/month, Riluzole 100 mg/day) nclusion Criteria _Healthy controls
• Age = 18 years
• Able to provide written informed consent prior to study participation
• Body weight of = 50 kg and a body mass index (BMI) between 19-30 kg/m2
• Vital signs measured after 3 minutes resting in the supine position must be within the

following ranges:

• oral body temperature: 35.0-37.5 °C
• systolic blood pressure: 90-140 mm Hg
• diastolic blood pressure: 50-90 mm Hg
• pulse rate: 40-90 bpm Exclusion Criteria_ALS-patients
• Previous participation in another clinical study involving trial medication within the preceding 12 weeks prior to [18F]RoSMA-18-d6 administration
• Tracheostomy or continuous assisted ventilation of any type, or any other significant pulmonary disorder not attributed to ALS
• Structural brain or spinal cord abnormalities on MRI (e.g. evidence of stroke, infarct, or other space-occupying lesion or structural abnormality in brain and/or spinal cord.)
• Significant illness within two weeks prior to dosing
• History of clinically significant drug allergy; history of atopic allergy (asthma, urticaria, eczematous dermatitis). A known hypersensitivity to the study drug or drugs similar to the study drug
• History of allergic reaction to drugs or anaphylactic shock.
• History of myocardial infarction or history of treated cancer[18F]RoSMA-18-d6 in ALS brain and spinal cord_ Version 1.1_29.11.2022 Page 45 of 98
• Current clinically significant systemic illness or symptoms (e.g., respiratory or cardiovascular disease) that may deteriorate or affect the patient's safety or ability to cooperate during the study.
• Gastrostomy
• Any medical condition known to have an association with motor neuron dysfunction or involving neuromuscular weakness or another neurodegenerative disease, e.g. Parkinson's Disease (PD) or Alzheimer's disease (AD), which might confound or obscure the diagnosis of ALS
• Major internal disorders (e.g. arterial hypertension, diabetes, evidence suggestive of liver or renal disease (bilirubin >1.6 mg/dL, creatinine > 150 µM).
• Presence of any concomitant life-threatening disease or impairment likely to interfere with functional assessment
• Donation or loss of 400 mL or more of blood within eight weeks prior to dosing.
• Clinically relevant abnormalities on blood screening (see 4.3.1)
• Use of any prescription drug with central action or over-the-counter (OTC) medication within two weeks prior to dosing, except ALS-medication and Paracetamol which are acceptable.
• Use of tobacco products in the previous three months
• History of drug (e.g. Cannabis) or alcohol abuse within 12 months prior to dosing
• Pregnancy or breast feeding

Exclusion criteria_healthy volunteers:

• Significant neurological or psychiatric disease
• Significant illness within two weeks prior to dosing
• History of clinically significant drug allergy; history of atopic allergy (asthma, urticaria, eczematous dermatitis). A known hypersensitivity to the study drug or drugs similar to the study drug.
• History of myocardial infarction or history of treated cancer
• Current clinically significant systemic illness or symptoms (e.g., respiratory or cardiovascular disease) that may deteriorate or affect the patient's safety or ability to cooperate during the study.
• Major internal disorders (e.g. arterial hypertension, diabetes, evidence of suggestive liver or renal disease (bilirubin >1.6 mg/dL, creatinine > 150 µM).
• Other clinically significant abnormality on physical, neurological, or laboratory examination that, in the opinion of the investigator precludes the patient from the study.
• Clinically significant abnormality on electrocardiogram (ECG) that, in the opinion of the investigator, precludes the patient from the study.
• A past medical history of clinically significant ECG abnormalities or a family history of a prolonged QT-interval syndrome.
• Structural brain or spinal cord abnormalities on MRI (e.g., evidence of stroke, infarct, or other space-occupying lesion or structural abnormality in brain and/or spinal cord). History of allergic disease or anaphylactic shock.
• Presence of any concomitant life-threatening disease or impairment likely to interfere with functional assessment
• Use of any prescription drug or over-the-counter (OTC) medication within two weeks prior to dosing. Paracetamol is acceptable.
• Use of tobacco products in the previous three months.
• History of drug (e.g. Cannabis) or alcohol abuse within 12 months prior to dosing.
• Participation in any clinical investigation within four weeks prior to dosing or any ever participation in a research study with an amyloid lowering objective.
• Donation or loss of 400 mL or more of blood within eight weeks prior to dosing.
• Clinically relevant abnormalities on blood screening (see 4.3.1)
• Significant radiation exposure, especially in the last quarter (either X-ray or nuclear medicine studies). Any earlier nuclear medicine studies.
• Pregnancy or breast feeding

Related Conditions & MeSH terms

• Amyotrophic Lateral Sclerosis
• Motor Neuron Disease
• Sclerosis

Intervention

Drug:
• [18F]-RoSMA-18-d6
[18F]-RoSMA-18-d6 will be administered intravenously by a bolus injection followed by a subsequent PET/CT-scan of the brain and the spine

Locations

Country	Name	City	State
Switzerland	Muskelzentrum/ALS-Clinic, Kantonsspital St. Gallen	St. Gallen

Sponsors (3)

Lead Sponsor	Collaborator
Markus Weber	ETH Zurich, University Hospital Inselspital, Berne

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Difference of [18F]RoSMA-18-d6 uptake in the brain and spinal cord between ALS patients (at baseline and day 360) and healthy, age- and gender-matched subjects, as assessed by PET and MRI to allow morphological mapping	Voxelwise maps of the total distribution volume (VT; ml g-; 1) of [18F]RoSMA-18-d6 are calculated using the Logan method (42) as well as compartmental modelling i.e., the evaluation of the microparameters of a two-tissue reversible binding model (43) Mean parametric maps for brain are calculated for the baseline and follow-up conditions in the controls and ALS patient groups. Furthermore, standardized uptake values (SUV) regarding tracer uptake after 15, 30, 60 and - if available - 90 minutes will be determined	Baseline and day 360
Secondary	[18F]RoSMA-18-d6 uptake at month twelve (360 days) compared with uptake at baseline as assessed by PET/CT of the brain and spinal cord.		Baseline and day 360
Secondary	Correlation of [18F]RoSMA-18-d6 uptake with corresponding ALSFRS-Score from baseline to day 360.		Baseline and day 360
Secondary	Correlation of [18F]RoSMA-18-d6 uptake with corresponding respiratory function measurements (FVC, SNIP) from baseline to day 360.		Baseline and day 360
Secondary	Correlation of the change of [18F]RoSMA-18-d6 endpoints (?-CB2R; baseline to day 360) with corresponding changes of the-ECAS score		Baseline and day 360